Literature DB >> 18401200

Relative cardiac expression of growth hormone receptor and insulin-like growth factor-I mRNA in congenital heart disease.

A Nygren1, J Sunnegårdh, K Albertsson-Wikland, H Berggren, J Isgaard.   

Abstract

GH may exert direct growth-promoting and metabolic actions on target tissues, but most of its effects are mediated by circulating (endocrine) or local (auto-/paracrine) IGF-I. The GH/IGF-I system has an important role in cardiac development and in maintaining the structure and function of the heart. A subgroup of children with pronounced heart defects will eventually need transplants, owing to congestive heart failure. Since the symptoms are often severe and may progress while waiting for surgery, it is necessary to develop supportive medical treatment. GH has been proposed as a therapeutic agent in adults with heart failure, but to date studies are lacking on children and more information is necessary. We have examined the expression of IGF-I mRNA and GH-receptor (GH-R) mRNA in children undergoing surgery for congenital heart disease. Eighteen children scheduled for open-heart surgery were included in the study. Right auricular biopsies were taken at the time of venous catheterization preceding cardiac bypass. The specimens were analysed using realtime PCR. We were able to show expression of both IGF-I mRNA and GH-R mRNA in the pediatric heart. The relative expressions were intercorrelated (r=0.75, p<0.001). GH-R mRNA correlated positively to standardized weight (r=0.65, p=0.004), body mass index (BMI) (r=0.59, p=0.01), and standardized BMI (r=0.59, p=0.01). IGF-I mRNA only correlated to BMI (r=0.50, p=0.04). This is the first study displaying cardiac expression of IGF-I mRNA and GH-R mRNA in children with congenital heart disease, although further studies are needed to define a role for GH in the treatment of these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18401200     DOI: 10.1007/BF03345590

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Growth hormone improves cardiac function in rats with experimental myocardial infarction.

Authors:  J Isgaard; V Kujacic; E Jennische; A Holmäng; X Y Sun; T Hedner; A Hjalmarson; B A Bengtsson
Journal:  Eur J Clin Invest       Date:  1997-06       Impact factor: 4.686

2.  Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy.

Authors:  Paul J R Barton; Leanne E Felkin; Emma J Birks; Martin E Cullen; Nicholas R Banner; Suzanne Grindle; Jennifer L Hall; Leslie W Miller; Magdi H Yacoub
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

3.  Growth hormone improves bioenergetics and decreases catecholamines in postinfarct rat hearts.

Authors:  E Omerovic; E Bollano; R Mobini; V Kujacic; B Madhu; B Soussi; M Fu; A Hjalmarson; F Waagstein; J Isgaard
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

4.  Differential recruitment of alpha 1- and beta-adrenoceptors in inotropic control of atrial child myocardium by endogenous noradrenaline.

Authors:  K Borthne; A Langslet; H Lindberg; T Skomedal; J B Osnes
Journal:  Acta Physiol Scand       Date:  2000-09

Review 5.  Current treatment and prognosis in children with functionally univentricular hearts.

Authors:  R Kaulitz; M Hofbeck
Journal:  Arch Dis Child       Date:  2005-07       Impact factor: 3.791

Review 6.  Growth hormone and the cardiovascular function.

Authors:  J Svensson; A Tivesten; J Isgaard
Journal:  Minerva Endocrinol       Date:  2005-03       Impact factor: 2.184

7.  Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.

Authors:  K J Osterziel; O Strohm; J Schuler; M Friedrich; D Hänlein; R Willenbrock; S D Anker; P A Poole-Wilson; M B Ranke; R Dietz
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

8.  Insulin-like growth factor I receptors in human cardiac myocytes and their relation to myocardial hypertrophy.

Authors:  T Toyozaki; M Hiroe; M Hasumi; T Horie; S Hosoda; T Tsushima; M Sekiguchi
Journal:  Jpn Circ J       Date:  1993-12

9.  Growth hormone prolongs survival in experimental postinfarction heart failure.

Authors:  Antonio Cittadini; Jörgen Isgaard; Maria Gaia Monti; Cosma Casaburi; Angela Di Gianni; Raffaella Serpico; Guido Iaccarino; Luigi Saccà
Journal:  J Am Coll Cardiol       Date:  2003-06-18       Impact factor: 24.094

10.  Grown-up congenital heart (GUCH) disease: current needs and provision of service for adolescents and adults with congenital heart disease in the UK.

Authors: 
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

View more
  4 in total

1.  Effect of Lactation on myocardial vulnerability to ischemic insult in rats.

Authors:  Sahar Askari; Alireza Imani; Hamidreza Sadeghipour; Mahdieh Faghihi; Zohreh Edalatyzadeh; Samira Choopani; Nasser Karimi; Sulail Fatima
Journal:  Arq Bras Cardiol       Date:  2017-04-20       Impact factor: 2.000

2.  Short-Term Evaluation of Left Ventricular Mass and Function in Children With Growth Hormone Deficiency After Replacement Treatment.

Authors:  E Gómez-Guzmán; M D Cañete; R Valle-Martos; R Cañete; M Valle; L Jiménez-Reina; J Caballero-Villarraso
Journal:  Front Pediatr       Date:  2018-06-19       Impact factor: 3.418

3.  Different thresholds of tissue-specific dose-responses to growth hormone in short prepubertal children.

Authors:  Ralph Decker; Anders Nygren; Berit Kriström; Andreas Fm Nierop; Jan Gustafsson; Kerstin Albertsson-Wikland; Jovanna Dahlgren
Journal:  BMC Endocr Disord       Date:  2012-11-01       Impact factor: 2.763

4.  Neonatal IGF-1/IGFBP-1 axis and retinopathy of prematurity are associated with increased blood pressure in preterm children.

Authors:  Anna Kistner; Jon Sigurdsson; Aimon Niklasson; Chatarina Löfqvist; Kerstin Hall; Ann Hellström
Journal:  Acta Paediatr       Date:  2013-12-17       Impact factor: 2.299

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.